secwatch.observer — SEC 8-K summary
======================================

Issuer:     SAB Biotherapeutics, Inc. (SABS)
CIK:        0001833214
Form:       8-K
Filed at:   2025-09-30T23:59:59+00:00
Accession:  0001193125-25-225119
Event type: leadership
Sentiment:  neutral
Materiality: 0.35
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Christine Hamilton and Jeffrey Spragens resign from SAB Biotherapeutics board; size cut to nine
--------------------------------------------------------------------------------

- Christine Hamilton and Jeffrey Spragens resigned as board members effective September 30, 2025.
- Board size reduced from 11 to 9 directors, per July 2025 letter agreement with RA Capital Healthcare Fund.
- Resignations were not the result of any disagreement with management or company policies.
- The changes follow terms of the company's July 2025 private placement of securities.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1833214/000119312525225119/0001193125-25-225119-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1833214/000119312525225119/sabs-20250930.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-225119

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer